| Serial Number | 79418919 |
| Word Mark | MINERVA IMAGING |
| Filing Date | Monday, February 3, 2025 |
| Status | 661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED |
| Status Date | Thursday, February 19, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| NOT AVAILABLE | "IMAGING" |
| Goods and Services | Pharmaceutical drug development services in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy; research of pharmaceuticals to treat cancer, cardiovascular disease, and cell therapy, including stem cell therapy; research relating to cancer, cardiovascular disease, and cell therapy, including stem cell therapy; pharmaceutical research and development related to cancer, cardiovascular disease, and cell therapy, including stem cell therapy; research on the subject of pharmaceuticals for cancer, cardiovascular disease, and cell therapy, including stem cell therapy; pharmaceutical research services in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy; clinical research and conducting clinical trials in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy; conducting clinical trials for pharmaceutical products in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy; providing medical and scientific research information in the field of pharmaceuticals and clinical trials for cancer, cardiovascular disease, and cell therapy, including stem cell therapy; providing information about the results of clinical trials for pharmaceutical products related to cancer, cardiovascular disease, and cell therapy, including stem cell therapy; pharmaceutical products development related to the treatment of cancer and cardiovascular disease; consulting services for others in the field of designing clinical trials related to cancer, cardiovascular disease, and cell therapy, including stem cell therapy; scientific and technical consulting and research services for the pharmaceutical industry in the fields of cancer, cardiovascular disease, and cell therapy, including stem cell therapy. |
| Goods and Services | Custom manufacture of pharmaceuticals for the treatment of cancer. |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, March 13, 2025 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, March 13, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Minerva Imaging ApS |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | DK |
| Event Date | Event Description |
| Thursday, March 13, 2025 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Sunday, March 16, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Sunday, March 16, 2025 | APPLICATION FILING RECEIPT MAILED |
| Friday, May 23, 2025 | NEW REPRESENTATIVE AT IB RECEIVED |
| Monday, July 14, 2025 | ASSIGNED TO EXAMINER |
| Thursday, July 17, 2025 | NON-FINAL ACTION WRITTEN |
| Friday, July 18, 2025 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Thursday, August 21, 2025 | REFUSAL PROCESSED BY MPU |
| Thursday, August 21, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, September 5, 2025 | REFUSAL PROCESSED BY IB |
| Thursday, February 19, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, February 19, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, February 19, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |